Beclabuvir

Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC50 of [1][2].

Product Specifications

CAS Number

[958002-33-0]

Product Name Alternative

BMS-791325

UNSPSC

12352005

Target

HCV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Beclabuvir.html

Concentration

10mM

Purity

99.94

Solubility

DMSO : ≥ 30 mg/mL

Smiles

O=C(N1C2CCC1CN(C)C2)[C@@]3(CN4C5=C(C6CCCCC6)C7=CC=C(C(NS(=O)(N(C)C)=O)=O)C=C47)[C@H](C8=CC(OC)=CC=C85)C3

Molecular Formula

C36H45N5O5S

Molecular Weight

659.84

References & Citations

[1]Gentile I, et al. Beclabuvir for the treatment of hepatitis C. Expert Opin Investig Drugs. 2015;24 (8) :1111-21|[2]Tatum H, et al. A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1. J Viral Hepat. 2015 Aug;22 (8) :658-64.